Barclays
HPTX

Barclays’s HYPERION THERAPEUTICS INC COM STK (DE) HPTX Stock Holding History

Barclays’s Portfolio HPTX Stock Details HPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,850
Closed -$129K – 7475
2015
Q1 		$129K Buy
2,850
+1,974
+225% +$59.1K ﹤0.01% 4678
2014
Q4 		$21K Buy
876
+719
+458% +$16.2K ﹤0.01% 6317
2014
Q3 		$4K Sell
157
-107
-41% -$2.66K ﹤0.01% 7287
2014
Q2 		$6K Sell
264
-205
-44% -$5.27K ﹤0.01% 7090
2014
Q1 		$11K Buy
469
+138
+42% +$3.74K ﹤0.01% 6908
2013
Q4 		$6K Sell
331
-314
-49% -$7.39K ﹤0.01% 7161
2013
Q3 		$17K Sell
645
-37
-5% -$927 ﹤0.01% 6608
2013
Q2 		$15K Buy
+682
New +$14.9K ﹤0.01% 6975

Barclays's HPTX Position: Q2 2015 in Review

Barclays sold out of HYPERION THERAPEUTICS INC COM STK (DE) (HPTX) in Q2 2015, closing a stake of 2,850 shares — an estimated $129K sold.

Barclays first reported a position in HPTX in Q2 2013 and held it in 8 quarters. The position peaked at $129K in Q1 2015. 0 funds tracked by Wall St. Rank hold HPTX as of Q2 2015.

  • Barclays reported no remaining HYPERION THERAPEUTICS INC COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Barclays sold 2,850 HYPERION THERAPEUTICS INC COM STK (DE) shares in Q2 2015, an estimated $129K.
  • Barclays first reported a position in HYPERION THERAPEUTICS INC COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Barclays's HYPERION THERAPEUTICS INC COM STK (DE) position peaked at $129K in Q1 2015.
  • 0 funds tracked by Wall St. Rank held HYPERION THERAPEUTICS INC COM STK (DE) as of Q2 2015.

Based on Barclays's 13F filing for Q2 2015, filed 14 Aug 2015.